Article Information
PMID
Published By
Print ISSN
0258-851X
Online ISSN
1791-7549
History
- Received October 23, 2020
- Revision received July 12, 2021
- Accepted July 15, 2021
- Published online August 17, 2021.
Copyright & License
Copyright © 2021 The Author(s). Published by the International Institute of Anticancer Research.
Author Information
- 1AntiCancer Inc, San Diego, CA, U.S.A.;
- 2Department of Surgery, University of California, San Diego, CA, U.S.A.;
- 3Department of Surgery, Chinjujeil Hospital, Jinju, Republic of Korea
- Correspondence to: Hye In Lim, Department of Surgery, Chinjujeil Hospital, Jinju, Republic of Korea. Tel: +82 1099330009, e-mail: vastprogress{at}naver.com
- Correspondence to: Robert M. Hoffman, AntiCancer, Inc, 7917 Ostrow St, San Diego, CA, 92111, U.S.A. Tel: +1 8586542555, e-mail: all{at}anticancer.com
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Immunohistochemical Evaluation of Tumor Characteristic Retention in Triple-negative Breast Cancer PDOX Models
- Engineered Methioninase-expressing Tumor-targeting Salmonella typhimurium A1-R Inhibits Syngeneic-Cancer Mouse Models by Depleting Tumor Methionine
- Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin
- Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem
- Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma
- [11C]Methionine PET vs. [18F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients
- Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma
- Induction of the DNA-Repair Gene POLQ only in BRCA1-mutant Breast-Cancer Cells by Methionine Restriction
- DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts
- Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet
- Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal Fibroblasts
- [11C] Methionine-PET Imaging as a Cancer Biomarker for Methionine Addiction and Sensitivity to Methionine-restriction-based Combination Chemotherapy
- Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
- Oral Installation of Recombinant Methioninase-producing Escherichia coli into the Microbiome Inhibits Colon-cancer Growth in a Syngeneic Mouse Model
- Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer